Abstract
Background:
The study was conducted to evaluate the effect of chemoembolization on pancreatic cancer liver metastases.Patients and Methods:
Thirty-two patients with pancreatic cancer liver metastases who had underwent chemoembolization (48 weeks intervals) were retrospectively enrolled into this study. Size based evaluation (RECIST) and survival indexes were assessed in general and for gender and number of lesions.Results:
71.87% of patients showed stable disease (SD), 9.37% partial response (PR) and 18.75% progressive disease (PD). Survival rate for 1-, 3-, and 5-years from first TACE was 60%, 25%, and 11% respectively. Median survival time was 16 months and for SD group was 20 months. Progression-free survival for 6 month, 1-, 3- and 5-years was 84%, 57.3%, 20%, and 10%, respectively. There was statistically significant difference between male and female patients in their response. Survival rate for 1- and 5-years for males was 80% and 14% and for females was 47% and 0%. There was no significant difference between oligonodular liver lesion (less than 5) and multinodular (more than 5) groups. Survival rate for 1-and 5-years for oligonodular was 84% and 14% and for multinodular was 50% and 0% respectively.Conclusions:
Repetitive TACE resulted in a relevant response for the control of liver metastases of pancreatic cancer with considerable median survival time. Interestingly, this study was limited by the low number of subjects to produce significant results.Full Text
Full text is available in PDF
Copyright
© 2014, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0) (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.